improving Survival in Pediatric T-cell Lymphoblastic Lymphoma

Hematology Meeting Reports, 2009

European Journal of …, 2008

From June 1989 through to November 1998, 121 children with newly diagnosed T-cell lymphoblastic lymphoma (T-LBL) were included in the EORTC 58881 trial conducted by the Children's Leukaemia Group. The therapy regimen was based on a Berlin-Frankfurt-Munster protocol, for a total ...

European Journal of Cancer, 2008

children with newly diagnosed T-cell lymphoblastic lymphoma (T-LBL) were included in the EORTC 58881 trial conducted by the Children's Leukaemia Group. The therapy regimen was based on a Berlin-Frankfurt-Munster protocol, for a total duration of 24 months. Cranial irradiation, prophylactic cranial and local, was omitted, even for patients with central nervous involvement at diagnosis.

Pediatric Blood & Cancer, 2012

Journal of Clinical Oncology, 2012

To examine population-based improvements in survival and the impact of clinical covariates on outcome among children and adolescents with acute lymphoblastic leukemia (ALL) enrolled onto Children's Oncology Group (COG) clinical trials between 1990 and 2005.

Pediatric blood & cancer, 2015

Treatment intensification was considered a suitable strategy to increase the cure rate of lymphoblastic lymphoma (LBL) in children. The AIEOP LNH-97 trial was run between 1997 and 2007 for newly diagnosed LBL in patients aged less than 18 years. Treatment schedule was based on the previous, LSA2-L2 derived, AIEOP LNH-92 protocol. Modifications included: increased dose of upfront cyclophosphamide and methotrexate, use of l-Asparaginase during induction therapy, intensive block therapy for slow responders, and late intensification ("Reinduction") for patients with advanced stage disease. Total therapy duration was 12 months for stage I and II, and 24 months for stage III and IV. Central nervous system prophylaxis did not include cranial irradiation. 114 eligible patients were enrolled, 84 males and 30 females; median age was 9 years. Complete remission was obtained in 98% of patients. After a median follow-up time of seven years, 29 patients failed due to progression of dise...

Pediatric Blood & Cancer, 2008

Journal of the Faculty of Medicine-Baghdad

Background: Lymphoblastic lymphomas (LBL) are neoplasms of precursor T cells and B cells, or lymphoblasts. The term lymphoblastic lymphoma has been used to describe predominantly lymph nodebased disease; however, clinical distinction between LBL and acute lymphoblastic leukemia (ALL) has been arbitrary and has varied among different studies and institutions Objectives: To determine the frequency of LBL among all Non-Hodgkin's lymphoma (NHL) patients in children and to study the clinical and pathological features of LBL and assess the treatment outcome. Methods: A retrospective study included 28 children with newly diagnosed LBL (based on morphology) below the age of 14 years over 8 years period from January 1st, 2000 to December 31st, 2007 All the patients except one were treated by modified Medical Research Council UK National Randomized Trial For Children and young Adult with Acute Lymphoblastic Leukemia (MRC UKALL) regimen, one patient was misdiagnosed as B-cell NHL and treated with United Kingdom Children's Cancer Study Group (UKCCSG) Non-Hodgkin's Lymphoma protocol. Results: LBL forms 28/376 (7.1%) among NHL diagnosed in Children Welfare Teaching Hospital (CWTH) in the same period. The median age was 8.95 years (range 2 to 13.25 years) with male to female ratio of 3.7:1. Lymphadenopathy was present in 22 (78 .6%) of patients. The median duration of onset of symptoms was 7.25 months (range 1 week to 18 months). In response to treatment, 20 (71.4%) patients achieved complete remission (CR), 1 (3.6%) died during induction and 7 (25%) patients were non-responder (4 died and 3 abandoned). Of the 20 patients who achieved complete remission (CR); thirteen (46.4%) remained in continuous complete remission with a median follow up of 32.3 months, 3 (10.7%) patients died while in CR in an average of 16.6 weeks, 2 (7.1%) patients abandoned treatment and 2 (7.1%) patients relapsed. Conclusion: The study showed a low frequency of LBL in comparison with other studies which might be due to inadequate diagnostic facilities which differentiate LBL from other types of NHL, low survival rate might be due to advanced stages at presentation in addition to abandonment of treatment in some patients.

Pediatric Blood & Cancer, 2016

4,5 * and for the SFCE and the EORTC children leukemia group Background. The treatment of children with T-cell lymphoblastic lymphoma (T-LBL) and precursor B-cell lymphoblastic lymphoma (pB-LBL) has improved during the last decades. However, patients with relapsed or refractory lymphomas still have a poor prognosis. Methods. We report the characteristics and evolution of T-LBL and pB-LBL relapses in two multicenter prospective studies (LMT 96, European Organization for Research and Treatment of Cancer 58951). Results. From 1997 to 2008, 194 patients were included in these studies (157 T-LBL; 37 pB-LBL); among them, 23 patients underwent relapse or progression (18 T-LBL and 5 pB-LBL). The median age was 7.7 years (range 1.4-16.3). The survival rate at 8 years was 8.7% (21 deaths). The median time from diagnosis to relapse was 9 months [1-69] and 11 months [1-45] for T-LBL and pB-LBL, respectively. Twenty-two patients received a second-line treatment but remission was achieved in only seven patients. In 10 patients, intensification with hematopoietic stem cell transplantation (HSCT) was performed and four of them had a second relapse. Two patients still alive had T-LBL, experienced relapses 15 and 69 months after diagnosis, and received HSCT. Relapse during the intensive phase and second-line treatment without HSCT were identified as risk factors for bad prognosis (P = 0.01). Conclusions. The results of second-line treatment, including intensive chemotherapy and HSCT, show that salvage treatment is still disappointing in controlling refractory forms. Early identification of patients at high risk of relapse is mandatory, allowing earlier intensification. Valid prognostic parameters, such as biological markers, are needed. International cooperation is warranted to collect more data on these rare diagnoses.

PEDIATRICS, 2008

Screening and follow-up of newborns for SCD is feasible in a developing country in Africa. Extra effort in tracking is necessary to ensure that infants with disease are found early and referred for medical management.